New Insights into Serotonin 5-HT4 Receptors : A Novel Therapeutic Target for Alzheimer's Disease?

Maillet, Marjorie; Robert, Sylvain J.; Lezoualc'h, Frank
April 2004
Current Alzheimer Research;Apr2004, Vol. 1 Issue 2, p79
Academic Journal
The serotonin 5-HT4 receptor mediates many physiological effects in the central nervous system. The recent molecular identification of 5-HT4 receptors and the development of selective 5-HT4 receptor ligands have led to many important new insights into the signalling pathways and the physiological roles of these G protein-coupledreceptors in neurones. With respect to neurodegenerative disorders, it is suggested that 5-HT4 agonists may represent a new avenue for the treatment of Alzheimer's disease. This mini-review will focus on recent in vitro and in vivo pharmacological and biochemical studies showing the involvement of 5-HT4 receptors in cognitive processes and the amyloid precursor protein processing. The potential use of 5-HT4 agonists for the treatment of AD will be discussed.


Related Articles

  • Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B and 5-HT1D subtypes. Sánchez-López, Araceli; Centurión, David; Vázquez, Erika; Arulmani, Udayasankar; Saxena, Pramod R.; Villalón, Carlos M. // Naunyn-Schmiedeberg's Archives of Pharmacology;Feb2004, Vol. 369 Issue 2, p220 

    Serotonin (5-hydroxytryptamine; 5-HT) is capable of inhibiting the tachycardic responses elicited by sympathetic stimulation, but not by exogenous noradrenaline, in pithed rats pre-treated with desipramine. More recently, it has been shown that this cardiac sympatho-inhibitory response to 5-HT,...

  • 5HT1 agonists. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p388 

    A definition of the term "5HT1 agonists," which refers to serotonin agonists, is presented.

  • Regulatory & Healthcare News.  // PharmacoEconomics & Outcomes News;6/12/2010, Issue 605, p15 

    The article reports on funding to be provided by New Zealand's drug subsidy agency Pharmac to the Donepezil-Rex brand of donepezil used for treating Alzheimer's disease and related types of dementia after it receives Medsafe approval.

  • Role of Serotonin in Alzheimer's Disease. Geldenhuys, Werner I.; Van der Schyf, Cornelis I. // CNS Drugs;2011, Vol. 25 Issue 9, p765 

    Mounting evidence accumulated over the past few years indicates that the neurotransmitter serotonin plays a significant role in cognition. As a drug target, serotonin receptors have received notable attention due in particular to the role of several serotonin-receptor subclasses in cognition and...

  • Recent Advances in the Discovery of Selective and Non-Selective 5-HT1D Receptor Ligands. Ward, Simon E.; Watson, Jeannette M. // Current Topics in Medicinal Chemistry;Mar2010, Vol. 10 Issue 5, p479 

    This article highlights recent advances in the discovery of new agonists, antagonists and partial agonists of the 5-HT1D receptor. The field of 5-HT1D agonists continues to deliver a number of new potential therapeutic agents, although advances in this field are now more focussed on the clinical...

  • The Emergence of Selective 5-HT2B Antagonists Structures, Activities and Potential Therapeutic Applications [General Reviews]. Poissonnet, G.; Parmentier, J. G.; Boutin, J. A.; Goldstein, S. // Mini Reviews in Medicinal Chemistry;Mar2004, Vol. 4 Issue 3, p325 

    5-HT2 receptors mediate a large array of physiological and behavioral functions in humans via three distinct subtypes: 5-HT2A, 5-HT2B and 5-HT2C. While selective 5-HT2A antagonists have been known for some time, knowledge of the precise role played by the 5-HT2B receptor was hampered by the...

  • Classical Neurotransmitters and Neuropeptides Involved in Generalized Epilepsy: A Focus on Antiepileptic Drugs. Werner, F.-M.; Coveñas, R. // Current Medicinal Chemistry;Nov2011, Vol. 18 Issue 32, p4933 

    We describe the alterations of classical neurotransmitters and neuropeptides in generalized epilepsy. A neuronal network in this disease is developed. Gamma aminobutyric acid (GABA) hypoactivity induces dopamine hyperactivity because dopaminergic neurons are affected by the inhibitory influence...

  • Theoretical studies on the interaction of partial agonists with the 5-HT receptor. Silva, Maria Elena; Heim, Ralf; Strasser, Andrea; Elz, Sigurd; Dove, Stefan // Journal of Computer-Aided Molecular Design;Jan2011, Vol. 25 Issue 1, p51 

    series of 51 5-HT partial agonistic arylethylamines (primary or benzylamines) from different structural classes (indoles, methoxybenzenes, quinazolinediones) was investigated by fragment regression analysis (FRA), docking and 3D-QSAR approaches. The data, pEC values and intrinsic activities (E)...

  • Palonosetron: A Viewpoint by Roberto M. Labianca. Labianca, Roberto M. // Drugs;2004, Vol. 64 Issue 10, p1133 

    Palonosetron is a new serotonin 5-HT receptor antagonist with a binding affinity at least 30 times higher than that of the other, conventional setrons, such as ondansetron, granisetron and dolasetron, and with a much longer plasma half-life. The clinical development programme of this molecule...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics